Over 3,700 people have contracted Ebola in the Democratic Republic of the Congo, with 1,657 dead and 708 recovered as of August 1st. Now, in a race against the outbreak's spread, researchers are testing an oral medicine that could prevent the disease in people exposed to confirmed cases—a potential breakthrough in a health crisis that's claimed more lives than any previous Ebola outbreak in the country.
The trial, led by the DRC's National Institute for Biomedical Research alongside international partners, has enrolled over 25 patients in Ituri province. Participants receive the experimental drug for 10 days after confirmed high-risk exposure. The stakes are clear: there are currently no proven safe treatments, preventive medicines, or vaccines for the Bundibugyo species of Ebola that's driving this outbreak.
A Public Health System Under Strain
The response reveals both the urgency and the infrastructure challenges facing the DRC. A new 100-bed treatment center was inaugurated in Bunia, the capital of Ituri province. Since the outbreak was declared in mid-May, three testing sites have opened across the province, with a fourth launching this week. These aren't luxuries—they're necessities. Without safe places to monitor patients and deliver diagnostics, the trial can't expand, and neither can treatment access.
Vasee Moorthy, acting lead of WHO's R&D Blueprint, acknowledged the bottleneck. "We are trying to ramp up the enrolment," he said. "Because they're a clinical trial, we have to have safe, monitoring of the people that are enrolled in the trial. And that does take time to have more and more teams and more sites enrolling." The implication is stark: even as cases climb, the capacity to test potential solutions remains constrained.
Racing Toward a Vaccine
Parallel efforts are advancing on the vaccine front. Trials for the first-ever Bundibugyo-specific candidate vaccine began in the United Kingdom on July 24th, with a second trial starting in Canada this week. Both are being conducted on animal models—ferrets and monkeys—before results are analyzed by the WHO to determine whether human trials can proceed. Moorthy cautioned that definite conclusions likely won't emerge for several months.
The WHO's technical advisory group convened last Friday to review new data on Ervebo, a licensed vaccine targeting a different Ebola strain, and is expected to publish recommendations this week. The agency's preparation before the outbreak was declared in mid-May allowed trials to launch faster than in previous Ebola crises—a small advantage in a race against time.
International Support, Unequal Burden
The UN system is mobilizing resources. UNHCR is supporting screening and hygiene provision. A mobile laboratory at the DRC-Uganda border, backed by WHO and the World Food Programme, delivers test results in one hour, serving over 94,000 people in a region where delays cost lives. UNICEF operates nurseries for children of Ebola-affected families. The MONUSCO peacekeeping mission protects civilians and supports WHO teams. OCHA released up to $60 million through the UN's Global Emergency Fund to support response and preparedness in the DRC and neighboring countries.
Yet the reality remains: the DRC, one of the world's poorest nations, faces the world's largest Ebola outbreak on record. The burden falls heaviest on those with the least access to healthcare, information, and resources. International coordination matters. So does sustained funding, robust health infrastructure, and the speed at which experimental treatments can move from trials to the people who need them.
Why This Matters:
The DRC Ebola outbreak represents a collision between disease, poverty, and the limits of global health preparedness. Over 3,700 cases and counting expose how quickly a pathogen spreads when health systems are underfunded and communities lack diagnostic access. The oral prophylaxis trial and vaccine development show what's possible when research institutions and international bodies move quickly—but they also reveal how slow "quickly" still is when lives are being lost daily. The real test isn't whether these interventions work in trials. It's whether they'll reach the people who need them before the outbreak overwhelms the fragile infrastructure attempting to contain it. That requires sustained investment in the DRC's public health capacity, not just emergency response.